The U.S. FDA approved a pricey rare disease drug in September despite findings by its data reviewers that the treatment, ...

Treatments for asthma, chronic rhinosinusitis with nasal polyps, dyslipidemia, Cushing syndrome, gonorrhea, HSCT-associated thrombotic microangiopathy, marginal zone lymphoma, motion sickness, ...

The FDA has approved Kygevvi (doxecitine and doxribtimine) for the treatment of TK2d in adults and pediatric patients with an age of symptom onset on or before 12 years.

Intensifying competition, pricing pressure and copycat versions of its weight-loss drugs are holding back sales at the pharma ...

Sun Pharma is considering expanding its manufacturing in the U.S. due to new tariffs on medicines. CEO Richard Ascroft ...

With New Jersey voters electing U.S. Rep. Mikie Sherrill (D-NJ) to serve as the state’s next governor, there’s now a ...

Portfolio manager Eden Rahim sees biotech entering a new bull market amid lower rates, better trial data and renewed investor ...

A University of Manchester study funded by Breast Cancer Now and supported by Prevent Breast Cancer, reveals a drug approved ...

Participants in a multidisciplinary comprehensive obesity care model had clinically meaningful weight loss and high obesity ...

California voters' approval of Proposition 50 launches a new redistricting process likely to shift political power for rural ...